487 related articles for article (PubMed ID: 35534752)
1. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract][Full Text] [Related]
4. Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?
Darvishi A; Abdi Dezfouli R; Fazaeli A; Daroudi R; Zandieh N
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1201-1210. PubMed ID: 37768209
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
8. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
12. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M
Eur J Cancer; 2022 Jun; 168():12-24. PubMed ID: 35429901
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
14. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib plus fulvestrant in the treatment of breast cancer.
Neven P; Sonke GS; Jerusalem G
Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
